Clinical trials: 5-FU, completed
Neuroendocrine Tumors
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
Neuroendocrine tumors (NET) are rare but their incidence is growing. Alkylating agents (ALKY) are one of the main systemic treatments used, at least for advanced duodeno-pancreatic NETs, with a response rate of 30 to 40% and a…
- Trial name
- MGMT-NET (NCT03217097)
- Testing
- Oxaliplatin-based chemotherapy, Alkylating-based chemotherapy
- Where
- 19 sites in France
- Volunteers
- 116 people
- Sponsor
- Hospices Civils de Lyon
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
The main purpose of this study is to evaluate the efficacy of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach…
- Trial name
- RAINFALL (NCT02314117)
- Testing
- Ramucirumab, Capecitabine, Cisplatin
- Where
- 135 sites in United States, Argentina and 18 more
- Volunteers
- 645 people
- Sponsor
- Eli Lilly and Company
Recurrent Colorectal Carcinoma, Progressive Colorectal Carcinoma
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
Phase 1b, safety, pharmacokinetic, and efficacy, multicenter, dose-escalating Study of Imprime PGG™ Injection dosed in combination with Cetuximab and concomitant irinotecan therapy.
- Trial name
- NCT00545545
- Testing
- Imprime PGG 2 mg/kg, Imprime PGG 4 mg/kg, Cetuximab
- Where
- 2 sites in Philippines
- Volunteers
- 32 people
- Sponsor
- HiberCell, Inc.
Pancreas Cancer
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
The study's overall objectives are to evaluate the safety of anakinra in combination with standard chemotherapy regimens in patients with pancreatic ductal adenocarinoma, as well as to collect preliminary immune modulation and…
- Trial name
- NCT02021422
- Testing
- anakinra, Oxaliplatin, Irinotecan
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baylor Research Institute
Esophageal Cancer
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
This is an open-label, Phase 1/2 study to evaluate the safety of durvalumab (MEDI4736) in combination with oxaliplatin/capecitabine chemotherapy in metastatic/locally advanced oesophageal cancer (OC) and with neoadjuvant…
- Trial name
- NCT02735239
- Testing
- Durvalumab, Tremelimumab, Oxaliplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 73 people
- Sponsor
- Ludwig Institute for Cancer Research
HER-2 Positive Breast Cancer
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
The main purpose of this study is to confirm the high pathologic complete response rate after neoadjuvant chemotherapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Human Epidermal growth factor receptor2…
- Trial name
- NCT01340430
- Testing
- Trastuzumab
- Where
- 6 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Lucia Del Mastro,MD
Carcinoma of Unknown Primary, Colorectal Cancer
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Carcinoma of Unknown Primary, Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00004005
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
Lumbar Disc Herniation
Bladder Meridian Gua Sha for Lumbar Disc Herniation: Efficacy and CRP Regulation Via Cutaneous-Meridian-Visceral Axis in Shen Period
Based on the "Cutaneous Region-Meridian-Visceral" axis theory, in this study, we investigated clinical efficacy of the Gua Sha intervention on the Bladder Meridian during the Shen Period (3:00-5:00 p.m.) for lumbar disc…
- Trial name
- CRP (NCT07754422)
- Testing
- Control group（standard treatment and care）, Observation group（standard treatment supplemented with Gua Sha）
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Pancreatic Cancer
Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00602602
- Testing
- bevacizumab, fluorouracil, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Colorectal Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00556413
- Testing
- cetuximab, fluorouracil, irinotecan hydrochloride
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Rectal Cancer
A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer
This is an open-label, randomized phase II study. Patients will be randomly assigned to either FL or TS-1/irinotecan preoperative chemotherapy regimens by stratification.
- Trial name
- NCT01269216
- Testing
- 5-FU with leucovorin, TS-1 with Irinotecan
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Yonsei University
Pregnancy, Neonates
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)
The objective of follow-up study P05713 is to evaluate whether corifollitropin alfa (Org 36286) treatment for the induction of monofollicular growth in women who underwent ovulation induction (OI) in base study P05693…
- Trial name
- Care (NCT00702338)
- Testing
- corifollitropin alfa, recombinant Follicle Stimulating Hormone (recFSH), human Chorion Gonadotropin (hCG)
- Volunteers
- 1 people
- Sponsor
- Organon and Co
Metastatic Colorectal Cancer, KRAS Gene Mutation
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
The purpose of the Phase 1b/2 study is to determine the safety and efficacy of Onvansertib, administered orally, daily on Day 1-5 and Day 15-19 of each 28-day cycle, in combination with FOLFIRI + Bevacizumab, as second-line…
- Trial name
- NCT03829410
- Testing
- Onvansertib, Bevacizumab, FOLFIRI
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- Cardiff Oncology
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
This pilot and feasibility study studies how well nivolumab and combination chemotherapy work before surgery in treating patients with pancreatic cancer that could possibly be removed by surgery.
- Trial name
- NCT03970252
- Testing
- Fluorouracil, Irinotecan, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Colorectal Cancer
Biomarker Directed Treatment in Metastatic Colorectal Cancer
This pilot study is being mounted to assess whether treatment assignment by ERCC-1 gene expression status suggests better clinical results from historical experience in metastatic colorectal cancer (mCRC).
- Trial name
- NCT01703390
- Testing
- FOLFIRI + Cetuximab, modifiedFOLFOX6 + Cetuximab
- Where
- 11 sites in Austria
- Volunteers
- 47 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Anal Cancer
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00324415
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- AIDS Malignancy Consortium
Rectal Carcinoma
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Determine if genotype-directed neoadjuvant chemoradiation, using information from the thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging in high risk patients compared to historical…
- Trial name
- NCT00682786
- Testing
- 5FU, Radiation, Surgery of resectable lesions
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cancer
Chemotherapy and Radiation Following Pancreatic Surgery
To describe the overall survival and disease-free survival in pancreatic cancer patients treated with adjuvant chemoradiation with cisplatin, continuous infusion 5FU and interferon alpha followed by gemcitabine.
- Trial name
- NCT00660270
- Testing
- Pancreatic Surgery, Radiation therapy, Cisplatin
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Washington University School of Medicine
Metastatic Colorectal Cancer, Adjuvant Colorectal Cancer
Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients
The primary objective of this study is to evaluate whether the management of colorectal cancer (CRC) patients with 5-fluorouracil (5-FU) exposure optimization testing reduces 5-FU related toxicities and improves outcomes compared…
- Conditions
- Metastatic Colorectal Cancer, Adjuvant Colorectal Cancer, 5-FU Containing Therapy Regimens
- Trial name
- 5-FU RECORD (NCT02055560)
- Where
- 5 sites in United States
- Volunteers
- 146 people
- Sponsor
- Saladax Biomedical, Inc.
Esophageal Cancer
Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00258323
- Testing
- cisplatin, fluorouracil, Iressa
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.